Feasibility of comprehensive genomic profiling using endoscopic ultrasound-guided tissue acquisition with a 22-gauge Franseen needle

IF 1.4 Q4 GASTROENTEROLOGY & HEPATOLOGY

DEN open Pub Date : 2024-04-15 DOI:10.1002/deo2.365

Kazunaga Ishigaki, Yousuke Nakai, Go Endo, Kohei Kurihara, Kota Ishida, Shuichi Tange, Rintaro Fukuda, Shinya Takaoka, Yurie Tokito, Yukari Suzuki, Hiroki Oyama, Sachiko Kanai, Tatsunori Suzuki, Tatsuya Sato, Ryunosuke Hakuta, Tomotaka Saito, Tsuyoshi Hamada, Naminatsu Takahara, Aya Shinozaki-Ushiku, Mitsuhiro Fujishiro

{"title":"Feasibility of comprehensive genomic profiling using endoscopic ultrasound-guided tissue acquisition with a 22-gauge Franseen needle","authors":"Kazunaga Ishigaki, Yousuke Nakai, Go Endo, Kohei Kurihara, Kota Ishida, Shuichi Tange, Rintaro Fukuda, Shinya Takaoka, Yurie Tokito, Yukari Suzuki, Hiroki Oyama, Sachiko Kanai, Tatsunori Suzuki, Tatsuya Sato, Ryunosuke Hakuta, Tomotaka Saito, Tsuyoshi Hamada, Naminatsu Takahara, Aya Shinozaki-Ushiku, Mitsuhiro Fujishiro","doi":"10.1002/deo2.365","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>Comprehensive genomic profiling (CGP) test for solid tumors is now increasingly utilized in clinical practice, especially in pancreatobiliary cancer, and specimens obtained by endoscopic ultrasound-guided tissue acquisition (EUS-TA) are often submitted for tissue-based CGP test. In this study, we evaluated the feasibility of EUS-TA using a 22-gauge Franseen needle for the CGP test.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Consecutive patients with solid tumors who underwent EUS-TA using a 22-gauge Franseen needle, and whose tissue samples were pre-checked for suitability for CGP test, were included in this single-center, retrospective analysis. The success rates of appropriate sample collection for CGP evaluated by pathologists (1st quality control) and CGP test (2nd quality control) were evaluated. In addition, The EUS-TA slides were evaluated for the tissue area and tumor area content, using the image software.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 50 cases, with 78% of pancreatic cancer, were included in the analysis. A median of 3 passes of EUS-TA were performed with an adverse event rate of 4%. The success rates for 1st and 2nd quality control for CGP tests were 86% and 76%, respectively. The image analyses suggested EUS-TA specimen did not always fulfill CGP test criteria, with 18% of tissue area ≥16 mm<sup>2</sup> and 38% of tumor area content ≥20%, even in cases with successful CGP tests. The suction method yielded a significantly larger amount of DNA but without a significant difference in the multivariate analysis.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The present study demonstrated the feasibility of EUS-TA using a 22-gauge Franseen needle for CGP test.</p>\n </section>\n </div>","PeriodicalId":93973,"journal":{"name":"DEN open","volume":"4 1","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/deo2.365","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"DEN open","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/deo2.365","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

Comprehensive genomic profiling (CGP) test for solid tumors is now increasingly utilized in clinical practice, especially in pancreatobiliary cancer, and specimens obtained by endoscopic ultrasound-guided tissue acquisition (EUS-TA) are often submitted for tissue-based CGP test. In this study, we evaluated the feasibility of EUS-TA using a 22-gauge Franseen needle for the CGP test.

Methods

Consecutive patients with solid tumors who underwent EUS-TA using a 22-gauge Franseen needle, and whose tissue samples were pre-checked for suitability for CGP test, were included in this single-center, retrospective analysis. The success rates of appropriate sample collection for CGP evaluated by pathologists (1st quality control) and CGP test (2nd quality control) were evaluated. In addition, The EUS-TA slides were evaluated for the tissue area and tumor area content, using the image software.

Results

A total of 50 cases, with 78% of pancreatic cancer, were included in the analysis. A median of 3 passes of EUS-TA were performed with an adverse event rate of 4%. The success rates for 1st and 2nd quality control for CGP tests were 86% and 76%, respectively. The image analyses suggested EUS-TA specimen did not always fulfill CGP test criteria, with 18% of tissue area ≥16 mm² and 38% of tumor area content ≥20%, even in cases with successful CGP tests. The suction method yielded a significantly larger amount of DNA but without a significant difference in the multivariate analysis.

Conclusions

The present study demonstrated the feasibility of EUS-TA using a 22-gauge Franseen needle for CGP test.

Abstract Image

查看原文本刊更多论文

利用内窥镜超声引导下的 22 号弗兰森针采集组织进行综合基因组分析的可行性

目的实体瘤综合基因组图谱检测（CGP）在临床实践中的应用越来越广泛，尤其是在胰胆管癌中，通过内镜超声引导下组织采集（EUS-TA）获得的标本经常被用于基于组织的 CGP 检测。在本研究中，我们评估了使用 22 号 Franseen 针 EUS-TA 进行 CGP 检测的可行性。方法在这项单中心回顾性分析中，纳入了使用 22 号 Franseen 针进行 EUS-TA 的连续实体瘤患者，这些患者的组织样本已预先检查过是否适合进行 CGP 检测。评估了病理学家评估（第一次质控）和 CGP 检测（第二次质控）的合适样本采集成功率。此外，还使用图像软件评估了 EUS-TA 切片的组织面积和肿瘤面积含量。结果共有 50 个病例纳入分析，其中 78% 为胰腺癌。EUS-TA 的中位数为 3 次，不良事件发生率为 4%。第一次和第二次 CGP 检测质量控制的成功率分别为 86% 和 76%。图像分析表明，EUS-TA标本并不总是符合CGP检测标准，即使在CGP检测成功的病例中，也有18%的组织面积≥16平方毫米，38%的肿瘤面积含量≥20%。抽吸法获得的 DNA 数量明显较多，但在多变量分析中无显著差异。结论本研究证明了使用 22 号 Franseen 针进行 CGP 检测的 EUS-TA 的可行性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

DEN open

CiteScore

1.30

自引率

0.00%

发文量